Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Parasitic Diseases

ClinicalTrials.gov lists 2,283 trials for Parasitic Diseases or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 180.

MeSH D010272 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 352 Phase 1/2 Phase 1/2 86 Phase 2 Phase 2 278 Phase 2/3 Phase 2/3 68 Phase 3 Phase 3 299 Phase 4 Phase 4 269 Not applicable Not applicable 455 Observational Observational 471 Phase 1 Phase 1 352 Phase 1/2 Phase 1/2 86 Phase 2 Phase 2 278 Phase 2/3 Phase 2/3 68 Phase 3 Phase 3 299 Phase 4 Phase 4 269 Not applicable Not applicable 455 Observational Observational 471

Trials per phase

2 more sections with rows

55 of the 2,283 trials are tagged with Parasitic Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Parasitic Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Parasitic Diseases trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 128

1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 2 trials (Observational 1, Phase 4 1) 1994: 1 trials (Phase 3 1) 1995: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1997: 3 trials (Observational 1, Phase 2 1, Phase 1/2 1) 1998: 4 trials (Observational 1, Not applicable 1, Phase 2 1, Phase 1 1) 1999: 8 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 2) 2000: 12 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 2, Phase 2 3) 2001: 15 trials (Observational 2, Not applicable 2, Phase 4 4, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 1) 2002: 27 trials (Observational 3, Not applicable 7, Phase 4 6, Phase 3 4, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2003: 44 trials (Observational 2, Not applicable 9, Phase 4 9, Phase 3 12, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 3) 2004: 58 trials (Observational 7, Not applicable 9, Phase 4 3, Phase 3 16, Phase 2/3 5, Phase 2 6, Phase 1/2 5, Phase 1 7) 2005: 70 trials (Observational 8, Not applicable 12, Phase 4 13, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 12) 2006: 98 trials (Observational 24, Not applicable 14, Phase 4 11, Phase 3 14, Phase 2 19, Phase 1/2 7, Phase 1 9) 2007: 94 trials (Observational 13, Not applicable 16, Phase 4 14, Phase 3 16, Phase 2/3 4, Phase 2 15, Phase 1/2 1, Phase 1 15) 2008: 64 trials (Observational 11, Not applicable 12, Phase 4 8, Phase 3 12, Phase 2/3 6, Phase 2 7, Phase 1/2 1, Phase 1 7) 2009: 84 trials (Observational 14, Not applicable 13, Phase 4 15, Phase 3 14, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 17) 2010: 99 trials (Observational 22, Not applicable 20, Phase 4 12, Phase 3 15, Phase 2/3 4, Phase 2 10, Phase 1/2 4, Phase 1 12) 2011: 102 trials (Observational 14, Not applicable 20, Phase 4 20, Phase 3 13, Phase 2/3 1, Phase 2 15, Phase 1/2 5, Phase 1 14) 2012: 98 trials (Observational 13, Not applicable 25, Phase 4 15, Phase 3 10, Phase 2/3 3, Phase 2 5, Phase 1/2 6, Phase 1 21) 2013: 89 trials (Observational 19, Not applicable 17, Phase 4 12, Phase 3 10, Phase 2/3 2, Phase 2 11, Phase 1/2 5, Phase 1 13) 2014: 114 trials (Observational 16, Not applicable 24, Phase 4 17, Phase 3 15, Phase 2/3 4, Phase 2 12, Phase 1/2 2, Phase 1 24) 2015: 103 trials (Observational 25, Not applicable 20, Phase 4 7, Phase 3 8, Phase 2/3 7, Phase 2 6, Phase 1/2 6, Phase 1 24) 2016: 113 trials (Observational 22, Not applicable 20, Phase 4 12, Phase 3 12, Phase 2/3 1, Phase 2 14, Phase 1/2 8, Phase 1 24) 2017: 85 trials (Observational 16, Not applicable 15, Phase 4 11, Phase 3 15, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 15) 2018: 97 trials (Observational 26, Not applicable 18, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 14, Phase 1/2 1, Phase 1 18) 2019: 97 trials (Observational 26, Not applicable 18, Phase 4 7, Phase 3 13, Phase 2/3 5, Phase 2 13, Phase 1/2 7, Phase 1 8) 2020: 73 trials (Observational 24, Not applicable 19, Phase 4 5, Phase 3 7, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 11) 2021: 128 trials (Observational 42, Not applicable 23, Phase 4 8, Phase 3 19, Phase 2/3 4, Phase 2 15, Phase 1/2 3, Phase 1 14) 2022: 99 trials (Other 1, Observational 23, Not applicable 22, Phase 4 13, Phase 3 8, Phase 2/3 3, Phase 2 11, Phase 1/2 2, Phase 1 16) 2023: 90 trials (Observational 25, Not applicable 21, Phase 4 10, Phase 3 3, Phase 2/3 3, Phase 2 7, Phase 1/2 4, Phase 1 17) 2024: 91 trials (Observational 26, Not applicable 21, Phase 4 9, Phase 3 12, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 8) 2025: 93 trials (Observational 19, Not applicable 24, Phase 4 10, Phase 3 9, Phase 2 15, Phase 1/2 2, Phase 1 14)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 67
2025 93
2024 91
2023 90
2022 99
2021 128
2020 73
2019 97
2018 97
2017 85

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 82 trials starting in 2026 and about 79 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 97 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 1,573 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Parasitic Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 352
Phase 1/2 86
Phase 2 278
Phase 2/3 68
Phase 3 299
Phase 4 269
Not applicable 455
Observational 471
Expanded access 4
Unknown 1

How many Parasitic Diseases trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 72
Recruiting 115
Enrolling by invitation 2
Active, not recruiting 41
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Parasitic Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 180
GlaxoSmithKline 56
U.S. Army Medical Research and Development Command 53
Centers for Disease Control and Prevention 39
Novartis Pharmaceuticals 32

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Parasitic Diseases? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Chloroquine 67
Primaquine 67
Albendazole 65
Ivermectin 49
Tafenoquine 27

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
1. Artemether-Lumefantrine (AL) 90
Dihydroartemisinine-Piperaquine 81
Pyrimethamine/sulfadoxine 47
Artesunate 38
PfSPZ (7G8) Challenge 28

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Parasitic Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malaria 1,969 32
Pneumonia 1,717 35
Gastroenteritis 1,361 26
Anaemia 1,052 19
Febrile convulsion 971 15

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Parasitic Diseases? (48)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19? The American journal of tropical medicine and hygiene 2020 Yes
Multifaceted roles of basophils in health and disease. The Journal of allergy and clinical immunology 2018 Yes
Characterisation of environmental enteropathy biomarkers and associated risk factors in children in the context of a WASH trial in Timor-Leste. International journal of hygiene and environmental health 2018 Yes
Sustained fecal-oral human-to-human transmission following a zoonotic event. Current opinion in virology 2017 Yes
Community Attitudes Toward Mass Drug Administration for Control and Elimination of Neglected Tropical Diseases After the 2014 Outbreak of Ebola Virus Disease in Lofa County, Liberia. The American journal of tropical medicine and hygiene 2016 Yes

Showing 5 of 48 publications.

Start your 14-day trial Email me all 48 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages